Natco Pharma has successfully completed closure of inspection and received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam.
The inspection by the US drug regulator was conducted during the period from January 30 to February 3, 2023, the Hyderabad-based company said in a release.
Natco Pharma’s scrip lost 1.57 per cent on the Bombay Stock Exchange on Friday to end at ₹629.55.
This is a Premium article available exclusively to our subscribers.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
You have reached your free article limit. Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...
TheHindu Businessline operates by its editorial values to provide you quality journalism.